11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment

Ocular peri-operative drugs

Diclofenac sodium
  • Single use eye drops 0.1% (£4.00 = 5 units)

Indications

  • For intraoperative and postoperative use

Notes

  1. Very few patients require long term therapy and this will usually be under the supervision of an Ophthalmologist
Ketorolac
  • Eye drops 0.5% (£3.00 = 5ml)

Indications

  • Prophylaxis and reduction of inflammation and associated symptoms following ocular surgery
Acetylcholine chloride
  • Injection 20mg in 2ml
Apraclonidine
  • Ophthalmic solution 0.5%
  • Single use ophthalmic solution 1%
Ethanol
  • Eye drops 18% (unlicensed preparation)
Fluorouracil
  • 6mg in 0.24ml to deliver 5mg injection (unlicensed preparation)
Hydroxypropyl methylcellulose (HPMC)
  • OcuCoat solution 2% (intraocular and topical)
  • Intraocular 2% in balanced salt solution
  • Topical solution 1%
Mitomycin
  • 0.2mg in 1ml syringe, 0.4mg in 1ml syringe (unlicensed preparation)
  • Eye drops 0.02%, 0.04% (unlicensed preparation)
Mydricaine
  • Formula 1 (unlicensed preparation)
  • Formula 2 (unlicensed preparation)
Sodium hyaluronate
  • Healonid® pre-filled syringe sodium hyaluronate 1% 0.85ml
  • Healonid® 5 pre-filled syringe 23mg in 1ml (0.6ml pre-filled syringe)
Viscoat®
  • Pre-filled syringe; sodium chondroitin sodium and sodium hyaluranate 0.5ml

Emergency use

Potassium ascorbate
  • Eye drops (equivalent to ascorbic acid 10%) (unlicensed preparation)
Sodium Citrate
  • Eye drops 10.11% (equivalent to citrate 6.5%) (unlicensed preparation)

Subfoveal choroidal neovascularisation

Aflibercept
  • Solution for intravitreal injection

Notes

  1. NICE TA294:Aflibercept solution for injection for treating wet-age related macular degeneration (July 2013)
  2. NICE TA305 - Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (February 2014)
  3. NICE TA346 - Aflibercept for treating diabetic macular oedema (July 2015)
  4. NICE TA409 - Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (September 2016)
  5. NICE TA486 - Aflibercept for treating choroidal neovascularisation (November 2017)
Pegaptanib
  • Solution for intravitreal injection 300 microgram vial

Notes

  1. NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (August 2008)
    1. Pegaptanib (Macugen) is not recommended for the treatment of wet age-related macular degeneration
Ranibizumab
  • Solution for intravitreal injection pre-filled syringes 1.65mg in 0.165ml
  • Solution for intravitreal injection vials 2.3mg in 0.23ml

Notes

  1. NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (August 2008)
    1. Ranibizumab ((Lucentis) is recommended as an option for the treatment of wet age-related macular degeneration only when criteria of the NICE TA are met0
  2. NICE TA274: Ranibizumab for treating diabetic macular oedema (February 2013)
  3. NICE TA283: Ranibizumab - macular oedema (retinal vein occlusion) (May 2013)
  4. NICE TA298: Ranibizumab for choroidal neovascularisation (November 2013)
Verteporfin
  • 15 mg powder for reconstitution and administration by IV infusion

Notes

  1. NICE TA68: Use of photodynamic therapy for age-related macular degeneration (September 2006)

Vitreomacular traction

Ocriplasmin
  • Solution for intravitreal injection vials 0.375mg in 0.3ml

Notes

  1. NICE TA297: Ocriplasmin for treating vitreomacular traction (October 2013)

 

Home > Formulary > Chapters > 11. Eye > 11.8 Miscellaneous ophthalmic preparations > 11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment

 

  • First line
  • Second line
  • Specialist
  • Hospital